QV Bioelectronics

QV Bioelectronics raises £2M in pre-Series A financing to complete pre-clinical studies and develop the GRACE device for brain tumor treatment.

QV Bioelectronics receives £860,000 from Innovate UK to develop the GRACE device for brain tumor treatment before entering clinical trials.

Collaboration between QV Bioelectronics and Incubate Bio advances the GRACE platform by analyzing molecular pathway data and simulating scenarios to guide pre-clinical development.

QV Bioelectronics secures £735k in seed financing to advance the GRACE implant for brain tumor treatment using electric field therapy and expand its team.

QV Bioelectronics adapts its electric field therapy technology to develop the first fully implantable device for treating Diffuse Midline Glioma, a highly aggressive childhood brain cancer.

Michaela Baek joins QV Bioelectronics as a summer intern, focusing on electric field therapy development for glioblastoma.

QV Bioelectronics develops GRACE, the first fully implantable electric field therapy device for brain tumors, backed by investors and neurosurgeons.

QV Bioelectronics welcomes Carl Daintree as Chief Operating Officer, bringing cross-functional experience in medical devices, pharmaceuticals, and biotech from start-ups to large corporations.

Kashmeera Koh joins QV Bioelectronics as a Biomedical Engineer, specializing in neuroscience, biomaterials, and biological modeling, with an MEng in Molecular Bioengineering from Imperial College London.

QV Bioelectronics hires Dr. Ashwin Narayanan, a cancer research scientist with over a decade of experience in glioma biology, including postdoctoral work on IDH-mutated gliomas.

Tomisin joins QV Bioelectronics as a Scientist in Cancer Biology, with expertise in DNA damage repair mechanisms and mitotic cell cycle regulation, following his PhD from the Genome Damage & Stability Centre.

GRACE is an implantable device platform for treating solid tumors, initially targeting glioblastoma, the most common primary brain tumor in adults.